glp 1 atrial fibrillation Impact of GLP-1 Receptor Agonist Therapy on Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis Glucagon-Like Peptide-1 Protects Against Atrial

Doctor-prescribed medication, 1:1 coaching and insurance support

Discover how GLP-1 agonists in transplant patients can safely manage post-transplant diabetes and weight gain

Most patients in both groups had no significant gastric retention at the time of EGD

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

These revealed similar peptide binding modes to that previously observed for GLP-1

but, weight-loss injections can support weight loss of around 15-25% on average.